LOINC long common name : Clot strength TXA2 receptor inhibited [Length fraction] in Blood by calculation;
LOINC short name : Clot strength TXA2-R inhib LenFr Bld;
LOINC description : A calculated value representing the relative amount of clotting strength (i.e., platelet
activity) that would remain in the presence of anti-platelet thromboxane A2 (TXA2)-receptor
inhibiting drugs. It is the portion of clotting strength due to factors other than
arachidonic acid, which activates platelets by a pathway that includes metabolism
to thromboxane A2 (TXA2), which binds to the TXA2 receptor. This result is used to
guide anti-platelet therapy decisions. For example, if a patient's baseline relative
clotting strength due to AA activation is 25% [LOINC: 94579-0], then treating that
patient with an anti-platelet TXA2 receptor inhibitor would only reduce clotting strength
by 25%, leaving a predicted 75% intact.;
Has method